Objective-Inducible expression of cyclooxygenase-2 (COX-2) and terminal prostaglandin synthases (tPGS) has been mainly analyzed in tumor, stromal, and inflammatory cells, and little is known about the regulation of prostanoid biosynthesis by endothelial cells. Here we characterize the profile of prostanoids produced by activated HUVECs and analyze the expression and activities of tPGS. Methods and Results-Enzyme immunoassays indicated increased endothelial prostanoid production after proangiogenic stimulation, but without parallel upregulation of tPGS. Endothelial prostanoid production instead depended on the induction of COX-2 and was abolished by COX-2 silencing or pharmacological inhibition. COX-2 is functionally coupled to prostacyclin and thromboxane synthases in HUVECs, but these cells show no detectable PGE 2 synthase (PGES) activity. Endothelial PGE 2 production is partly mediated by nonenzymatic decomposition of COX-2-derived PGH 2 , but endothelialproduced PGH 2 can also be metabolized enzymatically by microsomal PGES-1 in cocultured tumor cells. Conclusions-Our findings identify a novel transcellular metabolism of PGE 2 between the endothelial and tumor compartments. Given the role of PGE 2 as a mediator of COX-2 proangiogenic effects, transcellular metabolism of endothelial-derived PGH 2 is a potential target for treatment of pathological angiogenesis. (Arterioscler Thromb Vasc Biol. 2009;29:1131-1137.)
N umerous studies indicate that enzymes involved in the metabolism of AA and its products might contribute to tumor-induced angiogenesis. 1, 2 Cyclooxygenase-2 (COX-2), which converts AA into the prostanoid precursor PGH 2 , is induced by the proangiogenic factor VEGF, released by tumor cells. Moreover, proinflammatory cytokines such as IL-1␤ and TNF␣, potent COX-2 inducers, also have proangiogenic activity. 3 COX-2 expression is elevated in tumors, and genetic inactivation or pharmacological inhibition of COX-2 reduces tumor-induced neovascularization. 4 COX-2-associated angiogenesis is thought to be mediated by derived prostanoids, such as PGE 2 , PGI 2 , and TXA 2. Strong evidence exists for a link between PGE 2 and tumor angiogenesis; and of the PGES enzymes (cPGES, mPGES-1, mPGES-2), inducible mPGES-1 appears to be critical for tumor angiogenesis. 5 Moreover, in vivo models of TXAS or PGIS overexpression indicate proangiogenic effects for TXA 2 and antiantiogenic effects for PGI 2 . 6 Despite the evidence linking prostanoids to tumor angiogenesis, their mechanism of action is poorly understood. In particular, very little is known about the possible contribution made by the regulation of endothelial terminal prostanoid synthases. PGH 2 release by endothelium has been shown in vivo and ex vivo 7, 8 ; however, whether PGH 2 is transformed into final prostanoids in endothelial cells spontaneously or enzymatically is unknown.
We investigated the regulation of terminal prostaglandin synthases by VEGF and IL-1␤. Our results indicate that although endothelial cells express terminal prostanoid synthases, the key enzyme in the regulation of prostanoid biosynthesis in these cells is COX-2. COX-2-derived PGH 2 is released untransformed by endothelial cells, and can serve as a substrate for further metabolism to PGE 2 by mPGES-1 expressed in neighboring tumor cells. Transcellular biosynthesis of PGE 2 through endothelium-tumor cross-talk suggests a possible role of endothelium-derived PGH 2 in tumor angiogenesis.
Methods

Cell Culture and Reagents
HUVECs were cultured as described 9 and used within passages 1 to 4. A549 cells were from ATCC (# CCL-185) and cultured as described. 10 Cells were grown to confluence and serum-starved overnight before treatments.
VEGF 165 and IL-1␤ were from Peprotech (UK), and TNF-␣ from R&D Systems. Primary antibodies were sourced as follows: phospho-Erk-1,2 (Promega); ␣-Tubulin (Sigma); COX-1 and COX-2 (Alexis Biochemicals); mPGES-1, mPGES-2, cPGES, PGIS, and TXAS (Cayman). AA was from Nu-Chek-Prep and PGH 2 from Larodan Fine Chemicals (Sweden). SC-560 was from Cayman. Etoricoxib was a gift from Dr Godessart (Amirall Prodesfarma).
Sample Preparation, Prostanoid Measurement, and Immunoblot
After treatments, cell supernatants were removed for prostanoid quantification (EIA kits, Cayman), and cell monolayers lysed for immunoblot as described. 11
RNA Isolation and RT-PCR
Total RNA was isolated with Tripure Isolation Reagent (Roche Diagnostics), and 2 g were reverse transcribed to cDNA with MMLV-RT (Invitrogen, CA). Conventional and real-time PCR were conducted as indicated in the supplemental data (available online at http://atvb.ahajournals.org).
Terminal Prostanoid Synthase Activities
Enzyme activities were assessed as previously reported 12, 13 ; see the supplemental data for details.
Effect of COX Selective Inhibitors on Prostanoid Formation by Cytokine-Treated ECs
HUVECs were pretreated (1 hour) with 10 mol/L Etoricoxib (COX-2 inhibitor), 0.01 mol/L SC-560 (COX-1 inhibitor), or both. After 24-hour stimulation with VEGF (50 ng/mL) or IL-1␤ (10 ng/mL), samples were processed for prostanoid determination and immunoblot.
COX-1 and COX-2 Knockdown
siRNAs (Ambion) are listed in the supplemental data. HUVECs were transiently transfected with Oligofectamine (Invitrogen) (see supplemental data). After 24 hours, cells were stimulated with VEGF or IL-1␤, followed by prostanoid determination and immunoblot.
PGE 2 Assay in Supernatants of HUVECs Cocultured With A549 Cells
A549 tumor cells were pretreated with IL-1␤ and COX inhibitors before mixing with HUVECs. Confluent HUVECs were treated with COX inhibitors and IL-1␤ as required. After 24-hour coculture, supernatants were collected for PGE 2 determination. For further details, see the supplemental data.
Statistical Analysis
Data were analyzed by Student t test or by analysis of variance followed by the Newman-Keuls test. Differences were considered statistically significant at PϽ0.05.
Results
Prostanoid Biosynthesis by Resting and Activated Endothelial Cells
HUVECs were treated with proangiogenic cytokines (VEGF or IL-1␤), and PGE 2 , PGI 2 (determined as its stable breakdown product 6-keto PGF 1␣ ), and TXA 2 (as its stable breakdown product TXB 2 ) were measured in cell supernatants. VEGF and IL-1␤ increased production of all 3 prostanoids by Ϸ3to 5-fold ( Figure 1 ). However, whereas VEGF-triggered prostanoid synthesis peaked after 8 hours, the maximal IL-1␤-triggered prostanoid response required 24 hours (data not shown).
Endothelial Cell Expression of Terminal Synthases for PGE 2 , PGI 2 , and TXA 2
To investigate the mechanism underlying the increased prostanoid synthesis, we analyzed the mRNA and protein expression of the terminal prostaglandin synthases for PGE 2 (mPGES-1, mPGES-2, and cPGES), PGI 2 (PGIS), and TXA 2 (TXAS). Analysis by conventional and real-time RT-PCR detected expression of PGIS, TXAS, cPGES, and mPGES-2 in HUVECs; however, exposure to VEGF or IL-1␤ did not increase expression above the basal levels (supplemental Figure IA and IB). mPGES-1 mRNA was not detected in resting or activated HUVECs; however, expression was induced by IL-1␤ in A549 cells (supplemental Figure IC) , agreeing with previous reports. 10, 14 Effective activation of HUVECs by the stimuli was confirmed by Erk-1,2 phosphorylation (supplemental Figure IIA) . As previously reported, 15 VEGF upregulated COX-2 mRNA expression (supplemental Figure IIB) . Constitutive expression of cPGES, mPGES-2, PGIS, and TXAS proteins was detected in HUVECs and, as with the mRNA, their expression was unmodified by VEGF ( Figure 2A ). Constitutive expression of COX-1 was also unaffected by VEGF, whereas COX-2 protein was strongly induced ( Figure 2B ). IL-1␤ gave similar results (supplemental Figure III) . Agreeing with the mRNA data, mPGES-1 protein expression was not detected in resting or stimulated HUVECs, although mPGES-1 protein was induced by IL-1␤ in A549 tumor cells ( Figure 2C ). These results indicate that VEGF-and IL-1␤-stimulated increases in HUVEC synthesis of PGE 2 , PGI 2 , and TXA 2 are not the result of modulated tPGS expression or protein stability. 
Functional Coupling Between COX Enzymes and Terminal Prostaglandin Synthases in ECs
Traditionally, PLA 2 has been considered a rate-limiting step during prostanoid formation. 16 In our system, total cPLA 2 expression in activated HUVECs was unmodified by either VEGF or IL-1␤ at any time tested (supplemental Figure IVA and IVC). However, agreeing with previous studies, 17 VEGF and IL-1␤ induced phosphorylation of cPLA 2 within 15 to 30 minutes, correlating with increased cPLA 2 enzymatic activity (supplemental Figure IVA and IVB). Nevertheless, the rate of cPLA 2 activation in VEGF-or IL-1␤-treated HUVECs did not correlate with the observed increase in prostanoid production, which closely correlated with COX-2 induction.
COX enzymes are generally thought to be functionally coupled to terminal prostanoid synthases. 18 To investigate the coupling of COX isoenzymes to particular tPGSs, we measured endothelial prostanoid production in the presence of selective inhibitors of COX-1 (SC-560) 19 and COX-2 (Etoricoxib). 20 The inhibitors diminished PGE 2 , PGI 2 , and TXA 2 biosynthesis in resting and stimulated cells. Although Etoricoxib had a stronger effect on all prostanoids analyzed, SC-560 unexpectedly also partially inhibited prostanoid production, particularly in activated cells ( Figure 3A) .
The selectivity of COX inhibitors has been questioned 21, 22 ; therefore as an alternative we knocked down expression of COX isoenzymes with specific siRNAs. COX-1 or COX-2 protein was effectively and specifically suppressed, and knock-down of one did not alter expression of the other (supplemental Figure  VA) . COX-2 silencing corroborated the results obtained with Etoricoxib; however, unlike the data obtained with SC-560, suppression of COX-1 expression had no effect on the production of any prostanoid tested, irrespective of treatment ( Figure  3B ). This lack of effect might have been attributable to an absence of COX-1 enzymatic activity in our experimental system; however, COX-1 activity was detectable in Etoricoxibtreated COX-2-silenced HUVECs, both with and without IL-1␤ treatment (supplemental Figure VB) . These results suggest that even low concentrations of SC-560 affect COX-2 activity and provide evidence of preferential coupling between COX-2 and terminal prostanoid synthases in vascular endothelium.
Enzyme Activities of the Terminal Synthases for PGE 2 , PGI 2 , and TXA 2 in Activated ECs
The functional coupling to upstream COX isoenzymes of terminal prostanoid synthases appears to depend on their kinetic properties. 23 We therefore added PGH 2 to resting or stimulated HUVECs to test whether increased production of prostanoids by activated cells involves upregulation of the activities of tPGS enzymes. PGH 2 increased production of TXA 2 , PGI 2 , and PGE 2 , but the magnitude of this increase was unaffected by pretreatment with either VEGF or IL-1␤ ( Figure 4) . Surprisingly, control PGH 2 incubations in the absence of cells yielded similar amounts of PGE 2 to those produced by HUVECs (Figure 4 , upper panel, and supplemental Figure  VIA) . Moreover, the GC profile of HUVEC-produced prostanoids resembles the typical pattern of spontaneous chemical decomposition of PGH 2 , 24 with a predominance of PGE 2 and PGD 2 and a PGE 2 :PGD 2 ratio of about 3 (supplemental Figure  VIB) , strongly suggesting that HUVECs do not transform PGH 2 into PGE 2 enzymatically. This contrasts with A549 cells, which significantly increased PGE 2 production (supplemental Figure  VIA) , showing a single prominent PGE 2 peak characteristic of PGES activity (supplemental Figure VIB) .
Furthermore, knock-down of either cPGES or mPGES-2 did not affect the PGE 2 content in supernatants from IL-1␤-treated HUVECs, thus further confirming the absence of detectable PGES activity in these cells (supplemental Figure VII) .
These data therefore indicate that VEGF-and IL-1␤induced increases in PGI 2 and TXA 2 production by endothelial cells are not attributable to upregulation of the enzymatic activities of PGIS and TXAS. Furthermore, the lack of PGES activity in ECs indicates that PGE 2 production by HUVECs is nonenzymatic, and suggests that endothelium might act as a source of untransformed PGH 2 .
Transcellular PGE 2 Biosynthesis in Endothelial and Tumor Cocultures
Endothelium is known to release untransformed PGH 2 in certain situations, as homeostatic physiological interactions with platelets. 8 To investigate whether endothelium-derived PGH 2 serves as substrate for mPGES-1 expressed by neighboring tumor cells, we measured PGE 2 production by mixed cultures of HUVECs and A549 cells. A549 cells were activated with IL-1␤ to ensure optimal induction of mPGES-1, and control and activated cells were treated with COX-inhibitors (A549 COX-INHIB cells) to limit endogenous prostanoid production ( Figure 5A ). Coculture of activated A549 COX-INHIB cells with activated HUVECs yielded significantly greater amounts of PGE 2 than the sum of the productions by the individual cultures ( Figure 5B ). This increased production was impaired by pretreating HUVECs with COX inhibitors ( Figure 5B ), suggesting that HUVECs are the source of PGH 2 for transcellular metabolism by A549 cells.
In further experiments, A549 cells were seeded on microporous transwell inserts that allow passage of secreted products but prevent A549-HUVEC contacts. Under these conditions, there was no significant enhancement of PGE 2 synthesis ( Figure 5C ), suggesting that physical contact between A549 cells and HUVECs is necessary for tumor cell-mediated transcellular PGE 2 synthesis.
To confirm these findings, we examined PGE 2 production by HUVEC-A549 cocultures treated with AA. Exogenous AA induces the release of endothelial-derived PGH 2 to the extracellular medium, where it can be converted to PGF 2␣ by addition of the mild reducing agent SnCl 2 . 24 SnCl 2 thus provides a means of selectively inhibiting PGE 2 production from endothelial released PGH 2 . Mixed cultures of activated HUVECs and A549 COX-INHIB cells produced significantly more PGE 2 in response to exogenous AA than did activated HUVECs alone. This increased PGE 2 production was inhibited by pretreatment with SnCl 2 (Figure 6A ), supporting the existence of transcellular metabolism. In HUVECs cultured alone, SnCl 2 reduced PGE 2 production to the levels produced by nonactivated cells (Figure 6B ), suggesting that endothelial-derived PGE 2 is produced through nonenzymatic rearrangement of PGH 2 . SnCl 2 did not affect PGE 2 production by single A549 cultures ( Figure 6C ), indicating that these cells synthesize PGE 2 enzymatically.
Discussion
COX-2 dependence of tumor angiogenesis has generally been attributed to COX-2 expression in tumor or stromal cells. 1, 25 Our findings, however, support an important contribution by COX-2 expressed in endothelial cells. Moreover, our results provide evidence for a transcellular PGE 2 biosynthetic pathway in which endothelium-derived untransformed PGH 2 serves as substrate for mPGES-1 expressed by tumor cells, suggesting that that the tumor prostanoid profile reflects autocrine and paracrine interactions among the different tumor compartments. To our knowledge, this is the first report of PGE 2 production by transcellular metabolism through endothelial-tumor cell crosstalk, and provides insight into the complexity of prostanoid metabolism during angiogenesis. Given the limited current understanding of how pathways that control prostanoid production and function downstream of COX are regulated, one aim of this study was to characterize the expression and regulation of terminal prostaglandin synthases for PGE 2 , PGI 2 , and TXA 2 in vascular endothelial cells. Our results show that VEGF and IL-1␤, welldocumented angiogenesis inducers, 3 induce similar fold increases in the production of PGE 2 , PGI 2 , and TXA 2 by activated endothelial cells. Although PGI 2 is the main product of AA metabolism in vascular endothelium, 21 we detected PGE 2 and TXA 2 production under basal and activated conditions. The relative expression and characteristic kinetic parameters of tPGS enzymes are thought to be major determinants of the final profile of prostanoids produced by a given cell type, 18 and we therefore hypothesized that increases in the expression or enzymatic activities of these enzymes might contribute to enhanced prostanoid production. TXA 2 and PGI 2 can only be biosynthesized enzymatically, 26 and we consistently observed expression and activity of TXAS and PGIS in nonactivated cells (Figures 2A and 4) . The lack of any effect of VEGF or IL-1␤ on these parameters (Figures 2A and 4) suggests that the inducible production of TXA 2 and PGI 2 depends on upregulation of COX-2 and its functional coupling to TXAS and PGIS. Surprisingly, we did not detect mPGES-1 mRNA or protein in resting or stimulated endothelium. This contrasts with previous reports 27 but agrees with data obtained by Soler et al. 28 We used 2 independent sets of PCR primers and 2 antibodies, tools that effectively detected mPGES-1 mRNA and protein expression in A549 cells. Although such discrepancies have been ascribed to cell passage, 27 we did not detect mPGES-1 in HUVECs from different sources at any passage number (data not shown), and therefore the reason for this discrepancy is at present unknown. Moreover, although we detected constitutive expression of cPGES and mPGES-2 in endothelial cells, we did not detect terminal PGE 2 synthase activity; and silencing of these synthases did not affect PGE 2 production in activated HUVECs (Figure 4 , supplemental Figure VII) . The similar end-product profiles produced after incubation of PGH 2 with HUVECs or cell-free buffer strongly suggests that endothelial-derived PGE 2 forms through nonenzymatic decomposition of PGH 2 . This agrees with reports that PGE 2 and PGD 2 can be formed nonenzymatically, 24 and leaves open the question of what role cPGES and mPGES-2 play in endothelium, a subject of recent debate. 29, 30 It is possible that above a threshold concentration, endothelially-produced PGH 2 cannot be metabolized by the endothelial terminal synthases, particularly TXAS and PGIS, which likely undergo "suicide inactivation" in excess of substrate. 16, 31 Endothelial PGH 2 might then be released, taken up by neighboring cells and subsequently metabolized. Although most cells possess the complete set of enzymes for prostanoid biosynthesis, prostanoid production is often the result of cell-cell interactions that involve transfer of chemically reactive intermediates, a process known as transcellular biosynthesis. It is interesting that transcellular biosynthesis of PGE 2 was notable only when cells were pretreated with IL-1␤ before coculture. Because IL-1␤ induces COX-2 and triggers PGE 2 production dependent on COX-2 activity, overexpression and activation of COX-2 appears to be essential for production of PGH 2 sufficient for transcellular metabolism.
Endothelium-derived PGH 2 has been reported to be involved in the transcellular metabolism of TXA 2 by platelets 8 and of PGI 2 by lymphocytes. 32 Many tumor cells express functional mPGES-1, 5 and transcellular metabolism during tumor-endothelium cross-talk could be particularly important in tumor angiogenesis. In this scenario, endothelium would donate PGH 2 to neighboring tumor cells for metabolism by mPGES-1, thus increasing the total yield of PGE 2 . Our coculture experiments support this hypothesis. Mixed cultures of HUVECs and A549 produce higher amounts of PGE 2 than single cultures of either type, and the transwell experiments suggest that this effect is dependent on physical interaction. This also indicates that the enhanced PGE 2 production is not attributable to paracrine stimulation. 33 Additional evidence for the contribution of endothelialderived PGH 2 to transcellular metabolism comes from experiments with SnCl 2 , which substantially reduced PGE 2 production by HUVEC-A549 cocultures ( Figure 6A ). Furthermore, pretreatment of HUVECs with COX-inhibitors strongly impaired PGH 2 production and reduced PGE 2 biosynthesis in the HUVEC-A549 cocultures ( Figure 5 ).
Angiogenesis is generally believed to be regulated by the profile of downstream COX metabolites (determined by the expression and activities of their respective tPGSs) rather than by the total COX amount expressed in cells. 2 The establishment of COX-2 as the key enzyme regulating endothelial cell prostanoid production may have important implications for understanding of tumor-induced angiogenesis. COX-2 silencing or pharmacological inhibition abrogated basal and VEGF-or IL-1␤-induced production of PGE 2 , PGI 2 , and TXA 2 . Surprisingly, the experiments with selective COX inhibitors suggested a partial contribution of COX-1 to prostanoid production in resting and activated endothelial cells ( Figure 3A ). The fact that this effect was not observed when COX-1 expression was knocked down ( Figure 3B ) strongly suggests that the COX-1 inhibitor SC-560 affects COX-2 activity. This agrees with reports that, although COX-1 selective under cell-free conditions, SC-560 is not fully COX-1-selective in cells. 22 COX-1 activity detected in HUVECs (supplemental Figure  IVB) is unlikely to reflect a significant contribution of COX-1 to prostanoid biosynthesis, because it was measured in the presence of unphysiologically high concentrations of exogenous arachidonate. In contrast, prostanoid production experiments involve low concentrations of endogenous arachidonate, conditions under which COX-1 might be allosterically inhibited. 34 Functional coupling of COX-2 to PGIS is consistent with data linking COX-2 and PGI 2 , including the recently reported cardiovascular risk derived from COXIB-mediated inhibition of PGI 2 production. 21, 35 Regarding the functional coupling observed between COX-2 and TXAS, although TXA 2 production was originally linked to COX-1 activity, it can vary in heterologous systems expressing both COX isoenzymes. In fact, preferential coupling of TXAS to COX-2 has been reported in macrophages, 36 cancer cells, 37 and even healthy brain and kidney. 38 A previous study 13 reported a lack of PGE 2 and PGI 2 synthesis in resting HUVECs, associated with the lack of basal COX-2 expression in these cells. Our analysis, in accordance with others, 21, 39 clearly detects basal and cytokine-induced COX-2 expression and prostanoid production. COX-2 expression and PGI 2 production are upregulated under physiological blood flow, 40, 41 which would be consistent with the basal expression of COX-2 we detected.
The coculture experiments presented here establish the principle that endothelial prostanoids can be metabolized by neighboring tumor cells. However, further work will be needed to confirm the existence of transcellular prostanoid metabolism in vivo and to determine whether addition of proangiogenic cytokines to static cell cultures accurately models the tumor/vasculature interface. Transcellular metabolism of endothelial-derived PGH 2 illustrates the complex interactions between endothelium and other cell compartments. The use of endothelial prostanoid precursors to sustain pathological angiogenic signals provides a vivid demonstration of the ability of tumor cells to coopt an organism's pathophysiological responses and redirect them toward tumorigenic outcomes. Greater understanding of the complexity of prostanoid metabolism during angiogenesis, and of how complex autocrine and paracrine interactions determine tumor growth, is likely to provide new avenues for the development of treatments for pathological angiogenesis. 
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